The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated safety and efficacy data of combined KRAS G12C inhibitor (glecirasib, JAB-21822) and SHP2 inhibitor (JAB-3312) in patients with KRAS p.G12C mutated solid tumors.
 
Jun Zhao
No Relationships to Disclose
 
Jian Fang
No Relationships to Disclose
 
Yan Yu
No Relationships to Disclose
 
Qian Chu
No Relationships to Disclose
 
Xiaoyan Li
No Relationships to Disclose
 
Jiayan Chen
No Relationships to Disclose
 
Zhe Liu
No Relationships to Disclose
 
Li Zhang
No Relationships to Disclose
 
Lin Wu
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Hengrui Medicine; Innovate Biopharmaceuticals; Lilly; MSD; Pfizer; Roche China
 
Wu Zhuang
No Relationships to Disclose
 
XingYa Li
No Relationships to Disclose
 
Yanqiu Zhao
No Relationships to Disclose
 
Ligang Xing
No Relationships to Disclose
 
Lian Liu
No Relationships to Disclose
 
Chunmei Bai
No Relationships to Disclose
 
Xiaorong Dong
No Relationships to Disclose
 
Qibin Song
No Relationships to Disclose
 
Pinghua Pan
No Relationships to Disclose
 
Xuefeng Fang
No Relationships to Disclose
 
Jie Wang
No Relationships to Disclose